{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:48:36Z","timestamp":1779209316253,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173659"],"award-info":[{"award-number":["82173659"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202340236"],"award-info":[{"award-number":["202340236"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118370","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:50:06Z","timestamp":1763646606000},"page":"118370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P3","title":["Structural optimization and biological evaluation of 5-fluoro-7H-pyrrolo[2,3- d]pyrimidine derivatives as potent FAK inhibitors for the treatment of triple negative breast cancers (TNBC)"],"prefix":"10.1016","volume":"302","author":[{"given":"Dongping","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4519-1176","authenticated-orcid":false,"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118370_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118370_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40364-024-00558-0","article-title":"Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling","volume":"12","author":"Tan","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ejmech.2025.118370_bib3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118370_bib4","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejmech.2025.118370_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.semcancer.2019.07.028","article-title":"Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer","volume":"60","author":"Hill","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118370_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.semcancer.2020.03.002","article-title":"Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma","volume":"72","author":"Ronchi","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118370_bib7","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.3390\/cancers13153697","article-title":"Triple negative breast cancer: a Mountain yet to be scaled despite the triumphs","volume":"13","author":"Wu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118370_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"The BMJ"},{"key":"10.1016\/j.ejmech.2025.118370_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2025.118370_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115192","article-title":"Design, synthesis and evaluation of nitric oxide releasing derivatives of 2,4-diaminopyrimidine as novel FAK inhibitors for intervention of metastatic triple-negative breast cancer","volume":"250","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118370_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118370_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41422-023-00795-2","article-title":"Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial","volume":"33","author":"Liu","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2025.118370_bib13","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1073\/pnas.89.11.5192","article-title":"pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions","volume":"89","author":"Schaller","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.118370_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35010517","article-title":"FAK integrates growth-factor and integrin signals to promote cell migration","volume":"2","author":"Sieg","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118370_bib15","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/ijc.29522","article-title":"Targeting FAK scaffold functions inhibits human renal cell carcinoma growth","volume":"137","author":"B\u00e9raud","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118370_bib16","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1096\/fj.06-6545com","article-title":"FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K\/Akt pathway","volume":"21","author":"Thamilselvan","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2025.118370_bib17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1126\/science.1171837","article-title":"The increasing complexity of the cancer stem cell paradigm","volume":"324","author":"Rosen","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.118370_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000338278","article-title":"Intussusceptive angiogenesis: a biologically relevant form of angiogenesis","volume":"49","author":"De Spiegelaere","year":"2012","journal-title":"J. Vasc. Res."},{"key":"10.1016\/j.ejmech.2025.118370_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.118370_bib20","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.18632\/oncotarget.3023","article-title":"FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells","volume":"6","author":"Taliaferro-Smith","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118370_bib21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13046-019-1056-8","article-title":"Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells","volume":"38","author":"Rigiracciolo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118370_bib22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s12276-020-0447-4","article-title":"Targeting focal adhesion kinase in cancer cells and the tumor microenvironment","volume":"52","author":"Murphy","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118370_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/jcm8010038","article-title":"FAK is required for tumor metastasis-related fluid microenvironment in triple-negative breast cancer","volume":"8","author":"Pan","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118370_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2018.11.016","article-title":"Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting Integrin\/FAK and EGFR signaling","volume":"35","author":"Shen","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118370_bib25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4161\/cbt.9.10.11433","article-title":"Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models","volume":"9","author":"Walsh","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2025.118370_bib26","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.3390\/ijms23126381","article-title":"The development of FAK inhibitors: a five-year update","volume":"23","author":"Spallarossa","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118370_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106792","article-title":"Design, synthesis and biological evaluation of 4-arylamino-pyrimidine derivatives as focal adhesion kinase inhibitors","volume":"140","author":"Long","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118370_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113670","article-title":"Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents","volume":"223","author":"Tan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118370_bib29","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejmech.2019.05.048","article-title":"Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities","volume":"177","author":"Su","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118370_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12032-023-02092-9","article-title":"FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest","volume":"40","author":"Pan","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2025.118370_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127965","article-title":"Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton","volume":"40","author":"Mustafa","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118370_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106713","article-title":"Discovery of novel pyrrolo [2,3-d] pyrimidine derivatives as potent FAK inhibitors based on cyclization strategy","volume":"139","author":"Zeng","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118370_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111716","article-title":"Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents","volume":"183","author":"Wang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118370_bib34","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1073\/pnas.0805963106","article-title":"LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation","volume":"106","author":"Belkina","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.118370_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155408","article-title":"Circular RNAs and the JAK\/STAT pathway: new frontiers in cancer therapeutics","volume":"260","author":"Almalki","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejmech.2025.118370_bib36","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41417-021-00419-0","article-title":"Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-\u03b2 pathway","volume":"29","author":"Kang","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejmech.2025.118370_bib37","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R5900","article-title":"A mechanism of TNK1 activation by C-terminal gene truncation in human lymphomas","volume":"36","author":"Ashworth","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.ejmech.2025.118370_bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/jcp.10457","article-title":"MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2 in fibroblasts","volume":"199","author":"Kesavan","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2025.118370_bib39","doi-asserted-by":"crossref","first-page":"16348","DOI":"10.1021\/bi049866y","article-title":"Phosphoregulation of mixed-lineage kinase 1 activity by multiple phosphorylation in the activation loop","volume":"43","author":"Durkin","year":"2004","journal-title":"Biochemistry"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:09:00Z","timestamp":1777529340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S0223523425011353"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118370","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structural optimization and biological evaluation of 5-fluoro-7H-pyrrolo[2,3- d]pyrimidine derivatives as potent FAK inhibitors for the treatment of triple negative breast cancers (TNBC)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118370"}}